[针对复发性/逆转性急性髓性白血病的BCL-2和MCL-1的研究进展--评论]
Qian-Ying Ma1, Zi-Xiu Wei1, Juan Cheng1,2,3
1The First Clinical College of Lanzhou University, Lanzhou 730000, Gansu Province, China.
Zhongguo shi yan xue ye xue za zhi
|July 4, 2025
概括
向BCL-2和MCL-1为复发性/耐药性急性髓性白血病 (R/R AML) 提供了一个有希望的策略. 这种方法旨在通过抑制关键的抗亡蛋白来克服venetoclax耐药性,从而改善患者的治疗结果.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 复发性/耐药性急性髓性白血病 (R/RAML) 呈现出预后不佳,救援疗法选择有限.
- 癌细胞,包括R/RAML中的癌细胞,通常通过调节BCL-2和MCL-1等抗亡蛋白来逃避亡.
- 基于Venetoclax的疗法显示出前景,但由于新兴的耐药性而面临挑战.
研究的目的:
- 审查针对R/RAML的BCL-2和MCL-1的最新临床进展.
- 突出这些蛋白质在venetoclax耐药性的作用.
- 讨论选择性向作为一个可行的治疗策略.
主要方法:
- 最近临床试验和研究的文献综述.
- 在R/RAML中对venetoclax耐药性的机制的分析.
- 专注于针对BCL-2和MCL-1的药物的临床进展.
主要成果:
- 调节BCL-2和/或MCL-1的升级是venetoclax耐药性的主要机制.
- 预防性向BCL-2/BCL-XL/MCL-1可能会延迟或预防耐药性.
- 选择性抑制BCL-2和MCL-1是一种可行的治疗策略.
结论:
- 向BCL-2和MCL-1是克服R/RAML中venetoclax耐药性的关键策略.
- 这些抗亡蛋白的选择性抑制具有显著的治疗潜力.
- 持续的临床研究对于优化这些针对性疗法对R/RAML患者至关重要.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K